Duy Do

Duy Do

Auto-generated profile, based on publicly available information

Duy Do

Truveta, Inc

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2023 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
JTJasmine Tan-Kim
Jasmine Tan-Kim
NSNemi M. Shah
Nemi M. Shah
DDDuy Do
Duy Do
SMShawn A. Menefee
Shawn A. Menefee

16 December 2021 in Nursing Outlook
Verified
Journal Article
Closed access
ADAndrew Dierkes
Andrew Dierkes
DDDuy Do
Duy Do
HMHaley Morin
Haley Morin
MRMonica Rochman
Monica Rochman
DSDouglas Sloane
Douglas Sloane
MMMatthew McHugh
Matthew McHugh

15 May 2020 in Journal of Sleep Research
Verified
Journal Article
Open access
PDF file
DDDuy Do
Duy Do
Americans are increasingly consuming pharmaceuticals that although effective in treating their focal indication, include insomnia as a side effect. Regardless, no studies have documented trends in the concurrent use of these medications and their implications for insomnia among community‐dwelling adults. Using a nationally representative sample of US adults from the 1999–2016 National Health and Nutrition Examination Survey (NHANES), this study shows that the concurrent use of medications with insomnia as a potential side effect (“insomnia side effects” hereafter) has increased considerably in the past two decades. Between 1999 and 2016, the use of one and two or more medications with insomnia side effects increased by 66% and 164%, respectively. Compared to non‐users, respondents who took two or more of these medications were more likely to report insomnia symptoms (odds ratio [OR] = 1.78; 95% confidence interval [CI], 1.22 to 2.60), daytime sleepiness symptoms (OR = 1.73; 95% CI, 1.16 to 2.60) and difficulty with at least two daytime activities due to sleepiness or tiredness (OR = 1.96; 95% CI, 1.28 to 3.00). These findings highlight the need for insomnia screenings among patients who consume medications with insomnia side effects. They also emphasize the increased risks of insomnia associated with polypharmacy.

1 February 2020 in Journal of Health and Social Behavior
Verified
Journal Article
Open access
PDF file
JSJason Schnittker
Jason Schnittker
DDDuy Do
Duy Do
Sociologists have long struggled to explain the minority mental health paradox: that racial-ethnic minorities often report better mental health than non-Hispanic whites despite social environments that seem less conducive to well-being. Using data from the 2008–2013 Medical Expenditure Panel Survey (MEPS), this study provides a partial explanation for the paradox rooted in a very different disparity. Evidence from MEPS indicates that non-Hispanic whites consume more pharmaceuticals than racial-ethnic minorities for a wide variety of medical conditions. Moreover, non-Hispanic whites consume more pharmaceuticals that although effective in treating their focal indication, include depression or suicide as a side effect. In models that adjust for the use of such medications, the minority advantage in significant distress is reduced, in some instances to statistical nonsignificance. Although a significant black and Hispanic advantage in a continuous measure of distress remains, the magnitude of the difference is reduced considerably. The relationship between the use of medications with suicide as a side effect and significant distress is especially large, exceeding, for instance, the relationship between poverty and significant distress. For some minority groups, the less frequent use of such medications is driven by better health (as in the case of Asians), whereas for others, it reflects a treatment disparity (as in the case of blacks), although the consequences for the mental health paradox are the same. The implications of the results are discussed, especially with respect to the neglect of psychological side effects in the treatment of physical disease as well as the problem of multiple morbidities.

6 January 2020 in Journal of Aging and Health
Verified
Journal Article
Open access
PDF file
DDDuy Do
Duy Do
JSJason Schnittker
Jason Schnittker
Objectives: Many medications have cognitive impairment, memory loss, amnesia, or dementia as side effects (“cognitive side effects” hereafter), but little is known about trends in the prevalence of these medications or their implications for population-level cognitive impairment. Method: We use data from the National Health and Nutrition Examination Survey (1999–2016) to describe trends in the use of medications with cognitive side effects among adults aged 60+ (N = 16,937) and their implications for cognitive functioning (measured using word learning and recall, animal fluency, and digit symbol substitution assessments). Results: Between 1999 to 2000 and 2015 to 2016, the prevalence of older adults taking one, two, and at least three medications with cognitive side effects increased by 10.2%, 57.3%, and 298.7%, respectively. Compared to non-users, respondents who simultaneously used three or more medications with cognitive side effects scored 0.22 to 0.27 standard deviations lower in word learning and recall (p = .02), digit symbol substitution (p < .01), and the average standardized score of the three assessments (p < .001). Limitation: Dosage of medications associated with cognitive side effects was not measured. Discussion: Concurrent use of medications with cognitive side effects among older adults has increased dramatically over the past two decades. The use of such medications is associated with cognitive impairment and may explain for disparities in cognitive function across subgroups. These findings highlight the need for cognitive screenings among patients who consume medications with cognitive side effects. They also highlight the synergic effects of polypharmacy and potential drug-drug interactions that result in cognitive deficits.

3 April 2025 in American Journal of Preventive Medicine
Verified
Journal Article
Open access
DDDuy Do
Duy Do
PRPatricia J. Rodriguez
Patricia J. Rodriguez
SGSamuel Gratzl
Samuel Gratzl
BGBrianna Goodwin
Brianna Goodwin
CBCharlotte Baker
Charlotte Baker
NSNicholas L Stucky
Nicholas L Stucky
Syphilis incidence has increased significantly in the US, raising concerns about onward transmission. Using near-real-time data, this study examined monthly trends in syphilis incidence among US adults from January 2017 to October 2024, focusing on overall patterns and stratifying by demographic and clinical characteristics. Using Truveta Data - a large, diverse database of electronic health records from US healthcare systems - monthly syphilis incidence from January 2017 to October 2024 was calculated. Poisson regression models were used to assess trends, with adjustments for the early COVID-19 pandemic period. The analysis included 56,980,788 adults and 21,180 first-time syphilis cases, with a cumulative incidence of 35.9 per 100,000 person-years. Overall, incidence increased from 1.26 per 100,000 person-years in January 2017 to 4.88 in July 2022, then plateaued and declined to 2.47 by October 2024. The decline was larger among populations with high syphilis burdens, including men, younger adults, individuals identifying as American Indian/Alaskan Native or Native Hawaiian/Pacific Islander, those with behaviors associated with STI acquisition, those using Pre-exposure prophylaxis (PrEP) for HIV prevention, and individuals living with HIV. Conversely, incidence rose among populations with lower burdens: those without behaviors associated with STI acquisition, PrEP use, or living with HIV - implying a shift in the transmission dynamics. The findings highlight recent declines in syphilis incidence, primarily among high-burden groups, while syphilis incidence is rising in low-burden populations. These findings underscore the need to address factors contributing to syphilis transmission in diverse populations, including those that may not perceive themselves as vulnerable.